Search

1244447
393884
1257532
1240878
1195994
Final results from M72 AS01E TB Vaccine Trial
The final results from the M72AS01E TB vaccine study have been published in the New England Journal of Medicine. The vaccine demonstrated a 50% efficacy rate in the incidence of lung TB disease in HIV-negative adults, already infected with latent...
Community Engagement
Carina's Choice: SATVI collaborated with UCT Drama Department and Worcester Secondary School in developing this play which was performed by learners from Worcester Secondary School at 8 local high schools reaching approximately 8 000 adolescents in...
Phase 3 efficacy study finds shortened 4-month TB drug therapy treatment equivalent to 6-months therapy
The New England Journal of Medicine has published the results of a clinical study which shows that in a randomised phase 3 clinical trial, a shortened 4-month TB treatment was equivalent to the standard 6-month TB treatment.
2020 Annual Report
The SATVI 2020 Annual Report is available for download.
New multi-functional TB blood test validated
Researchers the South African Tuberculosis Vaccine Initiative (SATVI), the Center for Global Infectious Disease Research(USA) and a large consortium of collaborators have developed a validated a new, simple blood-based test that has the potential to...

News

Thursday, 23 September 2021
18 June 2021 Research published: HLA-DR marks recently divided antigen-apecific effector CD4 T Cells in active Tuberculosis patients

SATVI researchers have published a journal article titled "HLA-DR Marks recently divided Antigen-Specific effector CD4 T Cells in active Tuberculosis patients" appearing in the EBioMedicine journal.

Publication Date:
Wed, 14 Jul 2021 - 10:45
17 June 2021 Vacancy: Postdoctoral Fellowship in Single Cell Immunology

The South African Tuberculosis Vaccine Initiative is inviting applications for a Postdoctoral Fellowship in Single Cell Immunology.  CLOSED. 

Publication Date:
Thu, 17 Jun 2021 - 16:00
10 May 2021 Shortened 4-month TB treatment offers breakthrough in TB control.

The New England Journal of Medicine has just published the results of a clinical study which shows that in a randomised phase 3 clinical trial, a shortened 4-month TB treatment was equivalent to the standard 6-month TB treatment.  

 

Publication Date:
Mon, 10 May 2021 - 11:30
14 April 2021 A blood test to find those at high risk of tuberculosis in people living with HIV.

The Lancet Global Health journal reports the findings of a study of a host blood test that can find those at high risk of tuberculosis in people living with HIV. The blood mRNA biomarker differentiated between people living with HIV who had active tuberculosis from those without TB, and predicted which individuals would develop TB within 15 months.

Publication Date:
Wed, 14 Apr 2021 - 08:00

Pages